API market seen reaching $341.32 billion by 2030

By AI, Created 11:21 AM UTC, May 20, 2026, /AGP/ – The active pharmaceutical ingredients market is forecast to grow from $243.93 billion in 2025 to $341.32 billion by 2030, according to The Business Research Company. The report points to chronic disease growth, generic drug demand, biologics, and AI-enabled drug discovery as the main forces behind the expansion.

Why it matters: - Active pharmaceutical ingredients are the core compounds that give finished medicines their therapeutic effect. - Growth in the API market signals more demand for the raw materials behind prescription drugs, generics and biologics. - The forecast points to continued pressure on manufacturers, contract developers and drug supply chains as treatment demand rises.

What happened: - The Business Research Company projected the active pharmaceutical ingredients market will rise from $243.93 billion in 2025 to $260.71 billion in 2026. - The report forecast the market will reach $341.32 billion by 2030. - The company said the market is tracking a 6.9% compound annual growth rate in the 2025-2026 period and a 7.0% CAGR through 2030. - The report was released in London on May 6, 2026. - The company also published a free sample report and the full market report.

The details: - The report tied near-term API growth to higher chronic disease prevalence, stronger demand for generic medicines, more pharmaceutical R&D, better hospital and clinical infrastructure, and advances in chemical synthesis. - The forecast cited biologic drugs, precision medicine investment, targeted therapies, contract manufacturing services and artificial intelligence in drug discovery as additional growth drivers. - The report said key trends include personalized medicines, biologic API innovation, advanced drug delivery systems, stricter compliance and quality standards, and more outsourcing. - The report defined APIs as the substances in finished pharmaceutical products that produce pharmacological effects and help treat, prevent, mitigate or cure disease. - The report said APIs are also used to restore, correct or modify physiological functions in the human body. - The report cited rising chronic disease prevalence as a central market driver. - GOV.UK reported in March 2025 that type 2 diabetes prevalence in adults age 17 and older in England rose to 7.0% in March 2024 from 6.8% in March 2023. - The report said North America held the largest share of the API market in 2025. - The report also covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests API demand is shifting beyond traditional small-molecule drugs toward biologics, targeted therapies and personalized medicine. - More outsourcing and contract manufacturing point to a supply chain where specialized producers may capture more of the market as drugmakers seek scale and efficiency. - The AI drug discovery callout signals that the API market is being shaped by upstream innovation, not just manufacturing volume.

What’s next: - The market is expected to keep expanding through 2030 if chronic disease rates, generic-drug use and biologics adoption continue to rise. - Investment in precision medicine, AI and advanced manufacturing is likely to remain a focus for API producers. - Regional competition may intensify as North America leads and other major markets expand their manufacturing capacity.